- Full Year 2024 Terumo Corp Earnings Presentation TranscriptMay 14, 2024
- Q3 2024 Terumo Corp Earnings Presentation TranscriptFeb 07, 2024
- Q2 2024 Terumo Corp Earnings Presentation TranscriptNov 14, 2023
- Q1 2024 Terumo Corp Earnings Presentation TranscriptAug 09, 2023
- Full Year 2023 Terumo Corp Earnings Call TranscriptMay 15, 2023€14.2 (+0.71%)Earnings
- Q3 2023 Terumo Corp Earnings Call TranscriptFeb 09, 2023€13.3 (-1.48%)Earnings
- Q2 2023 Terumo Corp Earnings Call TranscriptNov 10, 2022€14.7 (-0.68%)Earnings
- Q1 2023 Terumo Corp Earnings Call TranscriptAug 09, 2022€15.4 (-3.75%)Earnings
- Full Year 2022 Terumo Corp Earnings Call TranscriptMay 12, 2022€13.6 (-2.86%)Earnings
- Q3 2022 Terumo Corp Earnings Call TranscriptFeb 09, 2022€15.75 (+3.06%)Earnings
- Terumo Corp New Growth Strategy Briefing TranscriptDec 16, 2021
- Q2 2022 Terumo Corp Earnings Call TranscriptNov 04, 2021€19.5 (+2.63%)Earnings
- Q1 2022 Terumo Corp Earnings Call TranscriptAug 04, 2021€16.3 (-1.21%)Earnings
- Full Year 2021 Terumo Corp Earnings Call TranscriptMay 12, 2021€15.2 (-1.30%)Earnings
- Q3 2021 Terumo Corp Earnings Call TranscriptFeb 04, 2021€17.1 (+4.27%)Earnings
- Q2 2021 Terumo Corp Earnings Call TranscriptNov 05, 2020€16 (+0.63%)Earnings
- Q1 2021 Terumo Corp Earnings Call TranscriptAug 06, 2020€15.9 (-1.24%)Earnings
- Full Year 2020 Terumo Corp Earnings Call TranscriptMay 18, 2020€16.6 (+7.79%)Earnings
- Q3 2020 Terumo Corp Earnings Call TranscriptFeb 06, 2020€16.6 (+2.47%)Earnings
- Q2 2020 Terumo Corp Earnings Presentation TranscriptNov 07, 2019
- Q1 2020 Terumo Corp Earnings Call TranscriptAug 08, 2019€13.21 (+2.88%)Earnings
- Full Year 2019 Terumo Corp Earnings Presentation TranscriptMay 09, 2019
Q3 2023 Terumo Corp Earnings Call Transcript
Hello. I am the CFO, Muto. I will give an overview of our earnings results for the third quarter of the fiscal year ending March 31, 2023. First, the highlights of this earnings announcement. Revenue continued to exceed JPY 200 billion as in Q2 for our highest ever result. When excluding FX impact, all companies and regions saw increased revenue, including China, where there were COVID-19 concerns. Profit increased over 30% year-on-year and expanded even further compared to Q2. We proactively raised prices at an expanded number of businesses and regions. We also continued activities from Q2 to rationalize our portfolio, completing the sale of the Nutrition business that was part of Hospital Care Solutions. We recorded a profit of JPY 3.9 billion from that sale.
In light of factors including the results up to Q3, we will revise our earnings guidance. We will revise our revenue guidance upward, primarily to reflect FX impact. We will revise our profit guidance downward to reflect unfavorable macro
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)